[1] CROSS M, SMITH E, HOY D, et al. The global burden of rheumatoid arthritis: Estimates from the global burden of disease 2010 study[J]. Annals of the Rheumatic Diseases, 2014, 73(7): 1316-1322. [2] FIGUS F A, PIGA M, AZZOLIN I, et al. Rheumatoid arthritis: Extra-articular manifestations and comorbidities[J]. Autoimmunity Reviews, 2021, 20(4): 102776. [3] 曾小峰,朱松林,谭爱春,等.我国类风湿关节炎疾病负担和生存质量研究的系统评价[J].中国循证医学杂志,2013,13:300-307. [4] LUO H F, PENG J, MA Q, et al. Intradermal acupuncture for rheumatoid arthritis: Study protocol for a randomised controlled trial[J]. Trials, 2021, 22(1): 450. [5] 王钢,王涛,党鹏.补肾祛寒治尪汤联合甲氨蝶呤治疗类风湿关节炎30例临床观察[J].中国中医基础医学杂志,2021,27(8):1298-1300. [6] 陈梦娜,刘健,齐亚军,等.基于关联规则和聚类分析挖掘刘健教授治疗类风湿关节炎的用药规律[J].风湿病与关节炎,2019,8:32-35. [7] XIE J G, WANG N, DING R K, et al. Association learning of Chinese herbal medicines and disease treatment efficacy[J]. International Journal of Production Research, 2019, 57(3): 683-702. [8] ALAGOZ O, HSU H, SCHAEFER A J, et al. Markov Decision Processes: A tool for sequential decision making under uncertainty[J]. Medical Decision Making, 2010, 30(4): 474-483. [9] CHHATWAL J, ALAGOZ O, BUMSIDE E S. Optimal breast biopsy decision-making based on mammographic features and demographic factors[J]. Operations Research, 2010, 58(6): 1577-1591. [10] BAZRAFSHAN N, LOTFI M M. A finite-horizon Markov decision process model for cancer chemotherapy treatment planning: An application to sequential treatment decision making in clinical trials[J]. Annals of Operations Research, 2020, 295(1): 483-502. [11] 刘克,曹平.马尔可夫决策过程理论与应用[M].北京:科学出版社,2015. [12] ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 Rheumatoid Arthritis classification criteria an American college of rheumatology/European league against rheumatism collaborative initiative[J]. Arthritis and Rheumatism, 2010, 62(9): 2569-2581. [13] COJOCARU M, COJOCARU I M, SILOSI I, et al. Extra-articular manifestations in rheumatoid arthritis[J]. Maedica (Bucur), 2010, 5(4): 286-291. |